flanders.bio is an independent life sciences cluster organisation based in Flanders, Belgium

flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.

News from flanders.bio and its members

Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law)

Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Van Herk Investments B.V. on 15 January 2018.

Finance | 16 January 18 Read more

Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law)

Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Marshall Wace LLP on 12 January 2018.

Finance | 16 January 18 Read more

BARC and Biogazelle announce collaboration for advanced genetic testing in clinical trials

Bio Analytical Research Corporation (BARC), the global central laboratory division of Cerba HealthCare, today announces that Biogazelle will join the pool of expert laboratories they consistently collaborate with.

Will 2018 be the year of biotech M&A? - An analysis by KBC Securities

In the Belgian biotech space, 2018 has started with a bang. With not even two full weeks into the new year, two Belgian biotechs have already received takeover bids from major pharma players. While Takeda and Tigenix seem to be aligned when it comes to the takeover story, Danish diabetes specialist Novo Nordisk appears to be having a more difficult time convincing its target of choice, Ablynx.

Finance | 15 January 18 Read more

flanders.bio events, trainings & international missions

Strategic Partners